Search Fighting Blindness
Access to therapies
Current Page: Orphan medicines
Orphan medicines
An orphan drug is a medicine that is developed for the diagnosis, prevention or treatment of a rare disease. A rare disease, sometimes referred to as an orphan disease, is any disease that affects a small percentage of the population. In Europe a condition is considered rare when it affects less than one in 2,000 people.
A pharmaceutical company developing a drug for a rare disease can apply to the European Medicines Agency (EMA) for orphan designation. The EMA Committee for Orphan Medicinal Products (COMP) is responsible for evaluating applications for orphan designation. Receiving orphan designation entitles the company to avail of a number of incentives, including reduced fees for regulatory activities and longer market exclusivity than non-orphan medicines.
Assessment of orphan medicines in Ireland
Orphan medicines are assessed in the same way as all other medicines. However patient organisations have been advocating for changes to the processes assessing orphan medicines for many years. As a result of this, in November 2018, as recommended in the National Rare Disease Plan 2014 – 2018, the Rare Diseases Technology Review Committee (RDTRC) was established. The committee, which includes two patient representatives, is responsible for assessing rare disease medicines that have received a negative recommendation from the National Centre of Pharmacoeconomics (NCPE) after a Health Technology Assessment (HTA). The committee examine the impact of the specific conditions on patients and care givers, real world evidence along with scientific data. It does not have the authority to approve drugs but will make recommendations to the HSE Drugs Committee who makes the final decision about drug reimbursements.
Stay up-to-date with our latest news in research, events and support services.
Last Name (required) *
Example: Yes, I would like to receive emails from Fighting Blindness. (You can unsubscribe anytime)
By submitting this form, you are consenting to receive marketing emails from: Fighting Blindness, 3rd Floor, Dublin 2, http://www.fightingblindness.ie. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
Fighting Blindness,
3rd Floor, 7 Ely Place,
Dublin 2, D02 TW98
Telephone: +353 1 6789 004
Email: info@fightingblindness.ie
Allergan International Foundation
Copyright © 2020 - Fighting Blindness | Reg Charity No 20013349 | Company No 109625